Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiff Oncology (CRDF) Current Deferred Revenue (2016 - 2018)

Historic Current Deferred Revenue for Cardiff Oncology (CRDF) over the last 4 years, with Q4 2018 value amounting to $486636.0.

  • Cardiff Oncology's Current Deferred Revenue rose 4551.47% to $486636.0 in Q4 2018 from the same period last year, while for Dec 2018 it was $486636.0, marking a year-over-year increase of 4551.47%. This contributed to the annual value of $486636.0 for FY2018, which is 4551.47% up from last year.
  • As of Q4 2018, Cardiff Oncology's Current Deferred Revenue stood at $486636.0, which was up 4551.47% from $472251.0 recorded in Q3 2018.
  • Over the past 5 years, Cardiff Oncology's Current Deferred Revenue peaked at $486636.0 during Q4 2018, and registered a low of $30614.0 during Q4 2015.
  • Moreover, its 4-year median value for Current Deferred Revenue was $298213.0 (2017), whereas its average is $313552.3.
  • Per our database at Business Quant, Cardiff Oncology's Current Deferred Revenue surged by 83175.02% in 2016 and then surged by 661.51% in 2017.
  • Quarter analysis of 4 years shows Cardiff Oncology's Current Deferred Revenue stood at $30614.0 in 2015, then surged by 831.75% to $285246.0 in 2016, then increased by 17.24% to $334424.0 in 2017, then soared by 45.51% to $486636.0 in 2018.
  • Its Current Deferred Revenue was $486636.0 in Q4 2018, compared to $472251.0 in Q3 2018 and $349565.0 in Q2 2018.